TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

Mobile site search icon.
Mobile navigation icon.

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

Rethink dosing and

Just one subcutaneous self-injection every 2 weeks, requiring no reconstitution1



for most patients in the clinical trial*





stomach, either thigh
or either arm

The recommended starting dose is 300 mg every 2 weeks. TAKHZYRO every 4 weeks is also effective and may be considered if the patient is well-controlled (eg, attack free) for more than 6 months.1

As recommended in the established HAE Treatment Guidelines, remind patients to always have acute treatment on hand.2 Patients taking TAKHZYRO should also be encouraged to periodically check the date of their acute treatment to see if it has expired.

*In clinical trials, the majority of patients self-administered TAKHZYRO within 10 to 60 seconds.

Dosing and administration at a glance

Dosing frequency
Once every 2 weeks (starting dose)
2 mL
~2 weeks
Non-plasma derived, recombinant mAb
Subcutaneous injection
How supplied
Ready-to-use single dose

Please see full Prescribing Information for detailed dosage and administration information.

Lexi, a real TAKHZYRO® patient, and her mother, Heather looking at a photo album.

Support patients with information on self-administration

TAKHZYRO is intended for self-administration or administration by a caregiver after being trained by a healthcare professional.1 In clinical studies, the majority of patients self-administered TAKHZYRO within 10 to 60 seconds.1 You can use the FDA-approved Instructions For Use information below to show patients the proper way to administer TAKHZYRO. And let patients know they can refer to supplementary injection training materials to reinforce your instructions:

FDA-approved Instructions For Use

Injection Training Materials overview

Instructions For Use video

Cell phone icon.

Keep patients on track

Even if your patients experience fewer or no attacks during treatment, talk to them about the importance of taking their medication as prescribed to help prevent future attacks.1

To support your efforts, patients can set up dosing reminders through the TAKHZYRO Text Reminder Program which will deliver reminders straight to their mobile phone whenever it's time to take TAKHZYRO.

Patients can sign up here

In addition to the Text Reminder Program, consider encouraging patients to keep a journal tracking their experiences with HAE. They can record questions for upcoming appointments and note potential triggers, and the date, severity and location of any swelling episodes. This will help you identify patterns over time and inform adjustments to your patient’s treatment plan.

Timing is dependent upon when the forms are received by OnePath®. The Quick Start Program is available to all commercially insured patients ≥12 years of age who are US residents with a confirmed diagnosis of HAE. Takeda and its affiliates reserve the right to change or discontinue this program at any time, without notice. Void where prohibited by law. This program does not constitute a financial assistance program.

References: 1. TAKHZYRO (lanadelumab-flyo) [prescribing information]. Lexington, MA: Dyax Corp 2018. 2. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema–the 2017 revision and update. Allergy. 2018;73(8):1575-1596.